Unió Europea - alemany - EMA (European Medicines Agency)

tmc pharma (eu) limited - fosdenopterin hydrobromide dihydrate - metal metabolism, inborn errors - anderen verdauungstrakt und stoffwechsel-produkte, - nulibry is indicated for the treatment of patients with molybdenum cofactor deficiency (mocd) type a.

Unió Europea - alemany - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - medikamente für obstruktive atemwegserkrankungen, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

Unió Europea - alemany - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - medikamente für obstruktive atemwegserkrankungen, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

Unió Europea - alemany - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol, mometasone furoate - asthma - medikamente für obstruktive atemwegserkrankungen, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Unió Europea - alemany - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol acetate, mometasone furoate - asthma - medikamente für obstruktive atemwegserkrankungen, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Unió Europea - alemany - EMA (European Medicines Agency)

roche registration gmbh  - risdiplam - muskelatrophie, spinal - andere medikamente für erkrankungen des muskel-skelett-systems - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.

Alemanya - alemany - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

mylan germany gmbh (8185157) - lacosamid - filmtablette - 100 mg - teil 1 - filmtablette; lacosamid (31188) 100 milligramm

Alemanya - alemany - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

mylan germany gmbh (8185157) - lacosamid - filmtablette - 150 mg - teil 1 - filmtablette; lacosamid (31188) 150 milligramm

Alemanya - alemany - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

mylan germany gmbh (8185157) - lacosamid - filmtablette - 200 mg - teil 1 - filmtablette; lacosamid (31188) 200 milligramm

Alemanya - alemany - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

mylan germany gmbh (8185157) - lacosamid - filmtablette - 50 mg - teil 1 - filmtablette; lacosamid (31188) 50 milligramm